# Sanofi's $180M Bet: Kill Every B Cell to End Autoimmune Relapse

- slug: sanofis-180m-bet-kill-every-b-cell-to-end-autoimmune-relapse
- date: 2026-03-23
- category: Biotech & Life Sciences

Sanofi Bets $180M on a San Mateo Startup's Plan to Reset the Immune System

Sanofi has licensed worldwide exclusive rights to KT501, a first-in-class trispecific T-cell engager developed by Kali Therapeutics, a small San Mateo startup that dosed its [first patient](https://www.prnewswire.com/news...

---